Pharma Focus Asia

OBiO Technology Plans to Open New Production Facility in Shanghai, China


OBiO Technology unveiled to construct new state-of-the-art GMP production facility, Intelli-M. for developing advanced therapies in Shanghai, China.


The Intelli-M facility covers an area of 828,000 square feet and is equipped with 29 production lines. It consists of a variety of single-use bioreactors ranging in size from 50 to 2000 litres and features closed downstream processing, allowing for flexibility.

The facility is well-equipped with advanced technologies to support the pharmaceutical and biotechnology sectors.

The site plays a pivotal role in enhancing production and service capabilities in both China and the United States. It covers activities from the proof of concept and investigational new drug (IND) declaration stages to new drug application and commercial manufacturing.

The new production facility will offer comprehensive services worldwide, catering to the increasing demand for contract development and manufacturing organisation (CDMO) solutions in the field of gene therapy accelerating the pace of innovation in the pharmaceutical industry.


Name   OBiO Technology
Type     New Construction

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference